SOURCE: Cardima, Inc.

June 13, 2008 08:45 ET

Dr. Jaswinder Gill, MD, FRCP to Present at the First Annual Europe AF Symposium, London, England on June 15, 2008

FREMONT, CA--(Marketwire - June 13, 2008) - Cardima, Inc. (OTCBB: CADM) Cardima is pleased to announce that Dr. Jaswinder Gill of Guy's and St. Thomas's Hospital will be giving a presentation titled, "Left and Right Linear Atrial Ablation Using a Novel System" at the upcoming first annual Europe AF Symposium. Cardima is a sponsor of this new and important meeting that will be headed by Co-Directors Dr. Riccardo Cappato (Milan, Italy) and Dr. Wyn Davies (London, UK). Leading electrophysiologists from around the world will be attending.

Dr. Gill will be speaking on his experience using the Cardima EP Ablation System at Guy's and St. Thomas's Hospital to treat patients with both paroxysmal and persistent atrial fibrillation. Dr. Gill is leading an independent study using the Cardima System and will present data to demonstrate that it can be used safely and effectively to replicate the Cox Maze procedure for the treatment of AF. To date, Guy's and St. Thomas's Hospital has treated over 110 AF patients using the Cardima EP Ablation System.

Cardima's CEO, Robert Cheney, commented: "Cardima feels it is important to be a sponsor of this new and important conference in the UK where our distributor, Dot Medical, is in the process of establishing commercial Cardima programs and training cardiac centers to use the Cardima EP Ablation System. We are especially pleased that the conference directors have selected Dr. Gill to give a talk. Dr. Gill will have an opportunity to present his extensive experience using our products to effectively treat AF at his hospital to leading electrophysiologists from around the world."

Earlier this year Dr. Gill had his abstract selected for presentation at the Fourth Annual Congress of the European Cardiac Arrhythmia Society (ECAS) in Marseille, France. This abstract was subsequently accepted for publication in the Journal of Interventional Cardiac Electrophysiology, vol. 22:1, 2008.

About Cardima

Cardima, Inc. has developed the PATHFINDER®, TRACER® and VUEPORT® Series of diagnostic catheters, the NAVIPORT® Series of guiding catheters, the REVELATION® Series of ablation catheters, the Surgical Ablation System with its series of ablation probes, and the INTELLITEMP® Energy Management Device Series for RF (radiofrequency) energy management. These devices are CE marked and/or received U.S. FDA 510(k) clearance. The REVELATION Series of ablation catheters with the INTELLITEMP EP Energy Management Device was developed and marketed for the treatment of atrial fibrillation (AF) with CE mark approval in Europe; it is not yet commercially available in the U.S.

For more information, please visit the Company's website at

Forward-Looking Statements

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those expressed in or implied by such forward-looking statements, including but not limited to using the Cardima System to demonstrate that it can be used safely and effectively to replicate the Cox Maze procedure for the treatment of AF. Potential risks and uncertainties include, but are not limited to: the uncertainties associated with the prospects for FDA approval of any new devices; the prospect for any future clinical trials or regulatory activities; the risk that the Company will not be able to raise additional capital in the immediate term as needed to continue operations and the risk that we will be unable to secure FDA approval for the EP ablation applications in the USA and CE mark for the Surgical Ablation probe series with Sheath. Additional risks and uncertainties are set forth in the Company's Annual Report on Form 10-KSB for the year ended December 31, 2007, the Company's Quarterly Report on Form 10-QSB and in the Company's other filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events or changes in the Company's plans or expectations.

Contact Information